Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation.

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. J Oncol. 2019;2019:5879616 Authors: Brocco D, Lanuti P, Simeone P, Bologna G, Pieragostino D, Cufaro MC, Graziano V, Peri M, Di Marino P, De Tursi M, Grassadonia A, Rapposelli IG, Pierdomenico L, Ercolino E, Ciccocioppo F, Del Boccio P, Marchisio M, Natoli C, Miscia S, Tinari N Abstract The recent introduction of the "precision medicine" concept in oncology pushed cancer research to focus on dynamic measurable biomarkers able to predict responses to novel anticancer therapies in order to improve clinical outcomes. Recently, the involvement of extracellular vesicles (EVs) in cancer pathophysiology has been described, and given their release from all cell types under specific stimuli, EVs have also been proposed as potential biomarkers in cancer. Among the techniques used to study EVs, flow cytometry has a high clinical potential. Here, we have applied a recently developed and simplified flow cytometry method for circulating EV enumeration, subtyping, and isolation from a large cohort of metastatic and locally advanced nonhaematological cancer patients (N = 106); samples from gender- and age-matched healthy volunteers were also analysed. A large spectrum of cancer-related markers was used to analyse differences in terms of peripheral blood circulating EV phenotypes between patients and healthy volunteers, as well as the...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research